TORONTO, Ontario, June 14, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today that Partner Lu Han Ph.D. has relocated to the firm’s office in Vancouver, British Colombia. Dr. Han will expand upon Lumira Ventures’ success in the region backing innovative companies including Aurinia Pharmaceuticals (NASDAQ: AUPH), ESSA Pharma (NASDAQ: EPIX) and Zymeworks (NYSE: ZYME).
“It has been inspiring to witness the amazing growth of the life sciences ecosystem in British Columbia over the last decade,” commented Dr. Han. “I look forward to building our presence in British Columbia and throughout western Canada and the Pacific Northwest. I’m excited to connect with the researchers, entrepreneurs and investors throughout the region. The combination of exceptional scientific talent, multiple emerging success stories, and the support of a strong local network make this region an incredibly exciting place to be for a life sciences investor today.”
Peter van der Velden, Managing General Partner, added “Lu has been an incredible part of our team’s success, and last year when we made the decision to build out our presence in western Canada, he immediately signaled that this was a role he wanted to take on. The decision to have Lu join Richard Glickman and build out our Vancouver team is an integral step in our firm’s continuing commitment to being an engaged and assessable partner to the institutions and entrepreneurs building transformative life sciences companies in North America. Having recently raised significant new capital in two investment funds, we are very well positioned to build on that foundation of success.”
About Lumira Ventures
Lumira Ventures is a North American healthcare venture capital firm with decades of experience investing in and building transformative biomedical companies. We are a multi-stage investor that partners with mission-driven entrepreneurs and like-minded investors to build innovative healthcare companies. These companies are harnessing rapidly evolving innovations in genomics, cell therapy, gene therapy, bioengineering, robotics, and artificial intelligence to develop high-impact, often transformative products for patients while generating exceptional returns for our investors and meaningful economic value to society. To date, Lumira’s companies have brought dozens of biomedical innovations to the market, impacting the lives of over 1 billion patients worldwide. Lumira Ventures manages its activities from offices in Toronto, Montréal, Vancouver and Boston.
For more information, please visit www.lumiraventures.com
Media Inquiries: firstname.lastname@example.org